Patents by Inventor Ahmet Kekec
Ahmet Kekec has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230406885Abstract: Provided are compounds of the Formula (I), or their pharmaceutically acceptable salts, wherein X1, X2, X3, A1, A2, R1-R7, R8a, R8b, R9a, R9b, R10 and R11 are as herein described. can trap IL-1? and are expected to have utility as therapeutic agents, for example, for treating cardiovascular disease and inflammatory disorders. The disclosure also provides pharmaceutical compositions which comprise the compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cardiovascular disease and inflammatory disorders and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: June 13, 2023Publication date: December 21, 2023Applicant: MERCK SHARP & DOHME LLCInventors: Faben A. Cruz, Danqing Feng, Zhuyan Guo, Jennifer Hanisak, Jennifer L. Hickey, Charles Lee Jayne, Ahmet Kekec, Michael Man-Chu Lo, Christopher W. Plummer, Elisabetta Bianchi, Stefania Colarusso, Emanuela Nizi, Francesca Pavone, Ali Munaim Yousif
-
Patent number: 11820805Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.Type: GrantFiled: December 13, 2018Date of Patent: November 21, 2023Assignee: MERCK SHARP & DOHME LLCInventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
-
Publication number: 20230365646Abstract: The present invention relates to insulin analogues and processes of making such insulin analogues by direct conversion of a free amine to an azide via diazo-transfer with an azotransfer agent.Type: ApplicationFiled: July 31, 2023Publication date: November 16, 2023Applicant: Merck Sharp & Dohme LLCInventors: Sobhana Babu Boga, Ahmet Kekec, Songnian Lin, Craig A. Parish, Weijuan Tang, Lin Yan
-
Publication number: 20230310551Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: August 24, 2021Publication date: October 5, 2023Applicant: Merck Sharp & Dohme LLCInventors: Christina B. Madsen-Duggan, Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Ravi Nargund, Christopher R. Moyes, Dmitri A. Pissarnitski, Zhicai Shi, Zhicai Wu, Lin Yan, Yuping Zhu
-
Patent number: 11530250Abstract: The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).Type: GrantFiled: March 18, 2019Date of Patent: December 20, 2022Assignee: MERCK SHARP & DOHME LLCInventors: Ahmet Kekec, Nancy Jo Kevin, Bing Li, Songnian Lin, Craig A. Parish, Weijuan Tang
-
Publication number: 20220273770Abstract: Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.Type: ApplicationFiled: July 23, 2020Publication date: September 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Erin N. Guidry, Pei Huo, Andrew J. Kassick, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Publication number: 20210198339Abstract: The present disclosure provides conjugates that comprise an insulin molecule conjugated via a conjugate framework to two or more separate ligands that each include a saccharide, wherein the framework, ligand, saccharide and insulin molecule optionally comprise a fatty chain (e.g., a C8-30 fatty chain), wherein when said insulin molecule is conjugated both to a C8-30 fatty chain and one or more separate ligands that each include a saccharide, said C8-30 fatty chain is linked to insulin molecule only, and wherein when the framework or ligand comprises a fatty chain the insulin molecule is conjugated to two or more separate ligands. In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile.Type: ApplicationFiled: December 13, 2018Publication date: July 1, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Danqing D. Feng, Yuping Zhu, Dmitri Pissarnitski, Chris Moyes, Songnian Lin
-
Patent number: 11041009Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: GrantFiled: March 19, 2018Date of Patent: June 22, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Yuping Zhu
-
Publication number: 20210177981Abstract: The present disclosure provides conjugates which comprise an insulin molecule conjugated via a conjugate framework to one or more separate ligands that include a first saccharide, and wherein the conjugate framework also comprises a fatty chain (e.g., a C8-30 fatty chain). In certain embodiments, a conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic (PK) and/or pharmacodynamic (PD) property of the conjugate is sensitive to serum concentration of a second saccharide. In certain embodiments, a conjugate is also characterized by having a protracted PK profile. Exemplary conjugates and sustained release formulations are provided in addition to methods of use and preparation.Type: ApplicationFiled: December 13, 2018Publication date: June 17, 2021Applicants: Merck Sharp & Dohme Corp., SmartCells, Inc.Inventors: Lin Yan, Pei Huo, Ahmet Kekec, Yuping Zhu, Dmitri Pissarnitski, Danqing D. Feng, Chris Moyes, Zhiqiang Zhao, David N. Hunter, Songnian Lin, Thomas M. Lancaster, Benjamin Chen
-
Publication number: 20210163568Abstract: The present invention relates to insulin analogues and processes of making such insulin analogues by direct conversion of a free amine to an azide via diazo-transfer with an azotransfer agent.Type: ApplicationFiled: April 8, 2019Publication date: June 3, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Sobhana Babu Boga, Ahmet Kekec, Songnian Lin, Craig A. Parish, Weijuan Tang, Lin Yan
-
Publication number: 20210002345Abstract: The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).Type: ApplicationFiled: March 18, 2019Publication date: January 7, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Ahmet Kekec, Nancy Jo Kevin, Bing Li, Songnian Lin, Craig A. Parish, Weijuan Tang
-
Patent number: 10800827Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 26, 2018Date of Patent: October 13, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10689430Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: May 23, 2017Date of Patent: June 23, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20200087375Abstract: An insulin conjugate comprising or consisting of a tri-valent sugar cluster is described. In particular aspects, the insulin conjugate displays a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: ApplicationFiled: March 19, 2018Publication date: March 19, 2020Applicant: Merck Sharp & Dohme Corp.Inventors: Danqing Feng, David N. Hunter, Pei Huo, Ahmet Kekec, Songnian Lin, Christopher R. Moyes, Ravi Nargund, Brenda Pipik, Dmitri A. Pissarnitski, Lin Yan, Zhiqiang Zhao, Yuping Zhu
-
Publication number: 20190177393Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: May 23, 2017Publication date: June 13, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
-
Publication number: 20190092833Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: November 26, 2018Publication date: March 28, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10183981Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: June 13, 2018Date of Patent: January 22, 2019Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Publication number: 20180291078Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: ApplicationFiled: June 13, 2018Publication date: October 11, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 10017556Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.Type: GrantFiled: November 19, 2015Date of Patent: July 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Yuping Zhu, Ahmet Kekec, Christina B. Madsen-Duggan, Zhi-Cai Shi, Zhicai Wu, Yingjun Mu
-
Patent number: 9868733Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention may be useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: GrantFiled: August 19, 2013Date of Patent: January 16, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: James M. Apgar, Tesfaye Biftu, Ping Chen, Danqing Feng, Jacqueline D. Hicks, Ahmet Kekec, Kenneth J. Leavitt, Bing Li, Iyassu Sebhat, Xiaoxia Qian, Lan Wei, Robert R. Wilkening, Zhicai Wu, Ashok Arasappan